18-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR™ Presented as Late Breaking Trial at VIVA
GENEVA, Oct. 11, 2021 /PRNewswire/ -- 18-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR™, MedAlliance's novel sirolimus-eluting balloon, for the treatment of long tibial occlusive lesions...
Sequential Skin raise US $1.65M in oversubscribed seed round to revolutionise skin health with their novel skin microbiome testing kit
LONDON, Oct. 11, 2021 /PRNewswire/ -- Sequential Skin Ltd, a UK/Singapore biotech start-up has raised US $1.65M in its oversubscribed seed round – to revolutionise the future of skin health. Sequential Skin team: Dr Oliver Worsley, CEO/cofounder (left), Petronille Houdart, PharmD and skincare director (middle), Dr Albert Dashi, CSO/cofounder (right). The round was led by Metaplanet,...
AXA BetterMe Weekend concludes successfully
HONG KONG, Oct. 10, 2021 /PRNewswire/ -- In response to the World Mental Health Day and celebrating the 1st anniversary of AXA BetterMe, the holistic wellness platform on the Emma by AXA app, AXA Hong Kong and Macau ("AXA") hosted the "AXA BetterMe Weekend" (the "Event") on 7-10 October at Hysan Place, Causeway Bay, to encourage Hong Kong citizens to take...
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk of Clinical Progression...
DURHAM, N.C. and BEIJING, Oct. 9, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced the filing of an emergency use authorization (EUA) application for its investigational SARS-CoV-2 (virus that causes COVID-19) combination therapy, BRII-196/BRII-198...
Winhealth-CARD Cooperation Boosts Rare Disease Healthy Ecosystem Construction
BOAO, China, Oct. 8, 2021 /PRNewswire/ -- On September 30, 2021 (Hainan-Bo'ao), Hongkong Winhealth Pharma Group (Winhealth Pharma) and the China Alliance for Rare Disease (CARD) officially signed a five-year strategic collaboration agreement. The cooperation involved rare disease registration and research, development of single disease diagnosis and treatment guidelines and regulations, doctor training & patient guide, etc. Winhealth Pharma will make...
My Dental Key: Democratizing Dental Education And Promoting Oral Health For All
NEW YORK, Oct. 8, 2021 /PRNewswire/ -- More than 3.5 billion people around the world suffer from oral health diseases, most of which can be prevented. According to data released by the World Health Organization, the combined global prevalence of tooth decay, gum disease, and tooth loss has plateaued at 45%. Increasingly, experts agree that moving the needle requires...
VIRALEZE™ antiviral nasal spray launched in ADMENTA Italia Group pharmacies in Italy
MELBOURNE, Australia, Oct. 8, 2021 /PRNewswire/ -- Australian biotech company Starpharma today announced it has signed a sales and distribution agreement for its VIRALEZE™ antiviral nasal spray with ADMENTA Italia Group (ADMENTA), a leading pharmaceutical retail and wholesale distribution company in Italy. The Italian over-the-counter pharmaceutical market is the third largest in Europe after Germany and the UK. VIRALEZE™ is expected...
Findings in New Book, Neurology in Migrants and Refugees, Presented at the World Congress of Neurology 2021, Raising Awareness on Neurological Issues Facing Migrants and Refugees
LONDON, Oct. 8, 2021 /PRNewswire/ -- Medical professionals around the world now have a new resource to help them understand the challenges of treating and caring for migrants and refugees with neurological problems, thanks to a new book authored by a Specialty Group of neurologists and neuroscientists under the auspices of the World Federation of Neurology (WFN). Neurology...
ProfoundBio Announces Presentation on Novel, Proprietary Linker-Drug Technology to Enable Antibody-Drug Conjugates (ADCs) with an Expanded Therapeutic Window at the AACR-NCI-EORTC International Conference
WOODINVILLE, Wash. and SUZHOU, China, Oct. 8, 2021 /PRNewswire/ -- ProfoundBio announces that preclinical data from its novel, proprietary ADC technology platform are being presented at the 2021 Molecular Targets and Cancer Therapeutics conference hosted by the American Association for Cancer Research (AACR), the National Cancer Institute (NCI), and the European Organisation for Research and Treatment of Cancer (EORTC). ...
Chubb to Acquire Cigna’s $3 Billion Premium Revenue Personal Accident, Supplemental Health and Life Insurance Business in Seven Asia-Pacific Markets for $5.75 Billion
- Acquisition further balances Asia's share of Chubb's global portfolio – from approximately $4 billion to $7 billion in net premiums written, or approximately 20% of the company (excluding China) - Global A&H premiums grow from $3.7 billion to $6.1 billion - Asia life company premiums increase from approximately $1 billion to $4 billion...
